MFA Wealth Advisors LLC Makes New Investment in Vera Therapeutics, Inc. $VERA

MFA Wealth Advisors LLC purchased a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 19,547 shares of the company’s stock, valued at approximately $631,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Engineers Gate Manager LP lifted its stake in shares of Vera Therapeutics by 1,579.2% in the second quarter. Engineers Gate Manager LP now owns 108,139 shares of the company’s stock valued at $4,640,000 after buying an additional 101,699 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Vera Therapeutics by 569.1% during the second quarter. Squarepoint Ops LLC now owns 104,937 shares of the company’s stock worth $4,503,000 after acquiring an additional 89,253 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Vera Therapeutics by 12.3% in the 2nd quarter. Arizona State Retirement System now owns 11,813 shares of the company’s stock worth $507,000 after acquiring an additional 1,295 shares during the last quarter. Nykredit A S bought a new position in Vera Therapeutics in the 2nd quarter valued at about $97,000. Finally, Readystate Asset Management LP bought a new position in Vera Therapeutics in the 2nd quarter valued at about $12,663,000. Institutional investors own 99.21% of the company’s stock.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total value of $684,500.00. Following the sale, the chief executive officer owned 235,244 shares of the company’s stock, valued at approximately $8,704,028. The trade was a 7.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Vera Therapeutics Stock Performance

Shares of VERA traded up $0.83 on Wednesday, reaching $30.25. 3,285,134 shares of the company’s stock traded hands, compared to its average volume of 1,626,524. The stock’s 50 day simple moving average is $32.91 and its two-hundred day simple moving average is $36.23. The stock has a market cap of $2.18 billion, a PE ratio of -5.16 and a beta of 1.06. Vera Therapeutics, Inc. has a 52-week low of $23.05 and a 52-week high of $56.05. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.06. During the same period in the prior year, the company posted ($1.20) earnings per share. On average, analysts forecast that Vera Therapeutics, Inc. will post -6.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on VERA shares. Raymond James Financial reissued a “strong-buy” rating on shares of Vera Therapeutics in a report on Tuesday, September 15th. Bank of America lifted their target price on Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. HC Wainwright decreased their price target on Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday, September 15th. Finally, Needham & Company LLC set a $125.00 target price on shares of Vera Therapeutics in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.15.

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s lead product candidate is atacicept, an investigational fusion protein designed to inhibit two immune signaling molecules, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which contribute to the survival and activity of antibody-producing B cells.

Vera is primarily studying atacicept as a potential treatment for immunoglobulin A nephropathy (IgA nephropathy), a chronic kidney disorder caused by the buildup of IgA immune complexes.